Skip Nav Destination
Issues
1 September 2011
-
Cover Image
Cover Image
Faber and colleagues demonstrate that expression of the pro-apoptotic Bcl-2 family member BIM predicts the capacity of selective kinase inhibitors to induce apoptosis in cancers addicted to EGFR, HER2, PI3K, or BRAF signaling. Evaluating BIM levels in tumor biopsies prior to chemotherapy therefore has the potential to predict which patients are most likely to respond to single-agent kinase inhibitor therapy. For details, please see the article by Faber and colleagues on page 352. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
News in Brief
News in Depth
Research Watch
Leukemia
Metastasis
Signaling
Multiple Myeloma
Urogenital Cancer
Metastasis
In the Spotlight
In Focus
Review
Research Articles
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
Si Tuen Lee-Hoeflich; Thinh Q. Pham; Don Dowbenko; Xander Munroe; James Lee; Li Li; Wei Zhou; Peter M. Haverty; Kanan Pujara; Jeremy Stinson; Sara M. Chan; Jeffrey Eastham-Anderson; Ajay Pandita; Somasekar Seshagiri; Klaus P. Hoeflich; Gulisa Turashvili; Karen A. Gelmon; Samuel A. Aparicio; David P. Davis; Mark X. Sliwkowski; Howard M. Stern
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller; Justin M. Balko; Emily M. Fox; Zara Ghazoui; Anita Dunbier; Helen Anderson; Mitch Dowsett; Aixiang Jiang; R. Adam Smith; Sauveur-Michel Maira; H. Charles Manning; Ana M. González-Angulo; Gordon B. Mills; Catherine Higham; Siprachanh Chanthaphaychith; Maria G. Kuba; William R. Miller; Yu Shyr; Carlos L. Arteaga
BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
Anthony C. Faber; Ryan B. Corcoran; Hiromichi Ebi; Lecia V. Sequist; Belinda A. Waltman; Euiheon Chung; Joao Incio; Subba R. Digumarthy; Sarah F. Pollack; Youngchul Song; Alona Muzikansky; Eugene Lifshits; Sylvie Roberge; Erik J. Coffman; Cyril H. Benes; Henry L. Gómez; José Baselga; Carlos L. Arteaga; Miguel N. Rivera; Dora Dias-Santagata; Rakesh K. Jain; Jeffrey A. Engelman
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds